Skip to main content

Atezolizumab combo in first-line NSCLC misses cost-effectiveness mark

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Atezolizumab combo in first-line NSCLC misses cost-effectiveness mark

User login

Username

Password

Reset your password

Type	Lead	score